transdermal


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to transdermal: Transdermal Drug Delivery System

transdermal

 [trans-der´mal]
entering through the dermis, or skin, as in administration of a drug applied to the skin in ointment or patch form. See also percutaneous. Called also transcutaneous.

transdermal

/trans·der·mal/ (-der´m'l) entering through the dermis, or skin, as in administration of a drug via ointment or patch.

transdermal

(trăns-dûr′məl, trănz-)
adj.
Through or by way of the skin: transdermal inoculation.

transdermal

adjective Referring to a medication applied topically (to the skin) and absorbed systemically.
 
noun A generic term for any agent administered topically and meant to be absorbed to manage systemic disease.

trans·der·mal

(trans.) (trans-dĕr'măl)
Entering through the dermis or skin, as in administration of a drug applied to the skin in ointment or patch form.
Synonym(s): topical administration.

trans·der·mal

(trans-dĕr'măl)
Entering through the dermis or skin.
Synonym(s): topical administration.

transdermal

across the skin, particularly with reference to the absorption of drugs applied topically for systemic effect.

transdermal patch
a drug-impregnated adhesive patch applied to the skin for controlled release of the active compound. See also fentanyl.
References in periodicals archive ?
Up-to-date one-stop information on transdermal drug delivery
The risk of VTE was not elevated among users of transdermal therapy (RR, 0.
Forecasts transdermal pain management product demand to 2016 by geographic region and product segment
Forecasts transdermal hormone replacement product demand to 2016 by geographic region and product segment
Developers and Marketers for Transdermal Medicine Rx Drugs/Biologics
Forecasts transdermal CNSt product demand to 2015 by geographic region and product segment
Examines active transdermal system design issues and evolving market factors
To expand the limits of transdermal drug delivery, developers are employing energy sources such as ultrasound, heat and electrical current to affect active transport through the skin.
Under the terms of the agreement, Altea Therapeutics has granted Lilly and Amylin exclusive worldwide rights to develop and commercialize transdermal exenatide utilizing the Altea Therapeutics proprietary PassPort[R] Transdermal Delivery System.
This report deals with transdermal drug delivery -- an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral, intravascular, subcutaneous and transmucosal routes.
To date, Altea Therapeutics has clinically studied the basal insulin transdermal patch in over 90 healthy subjects or people with type 1 diabetes.
Altea Therapeutics has entered into a research agreement with an undisclosed major pharmaceutical company to examine the feasibility of developing a transdermal patch product that delivers certain macromolecular carbohydrates for the treatment of coagulation disorders.